Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Atopic Dermatitis – Virtual Meet-Up #5

Register today! Space is limited for this Meet-Up series!
Live Virtual CE Meet-Up #5


Monday, September 19, 2022

2:30 PM – 3:20 PM EDT



Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


Atopic dermatitis (AD) is a chronic relapsing‐remitting inflammatory skin condition that affects an estimated 9.8% of children in the United States and is associated with significant disability and poor quality of life. Over the past decade, substantial progress has occurred in the development of advanced therapies capable of improving response in poorly controlled AD. It has been noted that a key challenge to the implementation of new AD therapies can be a lack of prescriber confidence from being unfamiliar with their respective mechanisms of action. Overcoming this requires up-to-date knowledge of AD pathophysiology, along with education on newer therapies that have been approved or are in late-stage development.  In addition to optimizing treatment selection, effective management strategies, such as shared decision-making and multidisciplinary care, play a key role in improving therapeutic response among patients with AD.

CME Meet-Ups
CME-certified Meet-Ups include a live expert faculty narration, case-based learning, and live peer-to-peer audience discussion. Attendance is limited to 25 participants.


2:30 PM – 3:00 PM Presentation & Case Study Discussion

3:00 PM – 3:15 PM Expert Access & Question/Answer Session


Anthony J. Mancini, MD, FAAP, FAAD
Head, Division of Dermatology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


This educational activity has been designed to meet the needs of dermatologists, senior dermatology residents, and other members of the healthcare team who manage treatment for patients with AD.


Upon completion of this educational activity, participants should be able to:

  • Describe the immunopathogenesis of AD
  • Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD
  • Apply evidence-based guideline recommendations to the treatment of patients with pediatric AD


There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the live broadcast
  • Complete the posttest and evaluation form at the end of the program

A statement of credit will be issued only upon receipt of a completed activity evaluation form. Your certificate will be sent to you within 4 weeks of receipt of the completed evaluation.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Anthony J. Mancini, MD, FAAP, FAAD
Advisory Board: Cassiopea, Castle Creek, Novartis
Consultant/Advisor: ParaPRO, Verrica
Speakers’ Bureau: Cassiopea, Sanofi Genzyme

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

Adobe® Flash® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


On the day of the program, you may access the event by going to:

Live Interactive Meet-Up:

There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 0.75 AMA PRA Category 1 CME creditTM . To do so, you must participate in the virtual livestream activity and complete the posttest and evaluation following the event. A statement of credit will be issued within 4 weeks of submission of a completed activity evaluation form.